Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, 17177, Stockholm, Sweden.
Curr Oncol Rep. 2022 Aug;24(8):1053-1062. doi: 10.1007/s11912-022-01270-8. Epub 2022 Apr 1.
The evolving information of the initiation, tumor cell heterogeneity, and plasticity of childhood neuroblastoma has opened up new perspectives for developing therapies based on detailed knowledge of the disease.
The cellular origin of neuroblastoma has begun to unravel and there have been several reports on tumor cell heterogeneity based on transcriptional core regulatory circuitries that have given us important information on the biology of neuroblastoma as a developmental disease. This together with new insight of the tumor microenvironment which acts as a support for neuroblastoma growth has given us the prospect for designing better treatment approaches for patients with high-risk neuroblastoma. Here, we discuss these new discoveries and highlight some emerging therapeutic options. Neuroblastoma is a disease with multiple facets. Detailed biological and molecular knowledge on neuroblastoma initiation, heterogeneity, and the communications between cells in the tumor microenvironment holds promise for better therapies.
儿童神经母细胞瘤的发生、肿瘤细胞异质性和可塑性的不断发展的信息为基于疾病详细知识的治疗方法的发展开辟了新的视角。
神经母细胞瘤的细胞起源开始被揭示,并且有几个关于基于转录核心调控回路的肿瘤细胞异质性的报告,这些报告为神经母细胞瘤作为一种发育性疾病的生物学提供了重要信息。这与肿瘤微环境的新见解一起,肿瘤微环境作为神经母细胞瘤生长的支持,为我们设计更好的高危神经母细胞瘤患者治疗方法提供了前景。在这里,我们讨论了这些新发现,并强调了一些新出现的治疗选择。神经母细胞瘤是一种具有多种特征的疾病。对神经母细胞瘤发生、异质性以及肿瘤微环境中细胞之间通讯的详细生物学和分子知识有望带来更好的治疗方法。